Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alector's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alector's regulatory disclosures and financial reporting.
Alector, Inc. reported Q2 2026 results showing collaboration revenue of $3.3 million, down from $7.9 million a year earlier, and a net loss of $23.0 million versus $30.5 million. For the first six months, the net loss was $45.9 million compared with $71.0 million in 2025.
Cash, cash equivalents, and marketable securities totaled $172.8 million as of June 30, 2026, and the company states this provides runway at least through 2027. Total liabilities were $212.8 million and stockholders’ equity was a deficit of $10.0 million, with deferred revenue of $162.9 million from its GSK collaboration.
GSK discontinued nivisnebart and latozinemab after unfavorable analyses and gave notice on July 6, 2026 to terminate the collaboration effective January 2, 2027. Alector is refocusing on its wholly owned ABC platform programs, including AL137 for Alzheimer’s disease, tau siRNA program AL064/AL164, and AL050 for Parkinson’s disease.
Alector, Inc. reported second quarter 2026 results and updated progress across its Alector Brain Carrier (ABC) blood-brain barrier platform. Collaboration revenue for the quarter ended June 30, 2026 was $3.3 million, down from $7.9 million a year earlier. Research and development expenses decreased to $19.5 million from $27.6 million, and general and administrative expenses declined to $8.3 million from $14.4 million, reflecting prior reductions in force and lower facilities and other costs. Net loss narrowed to $23.0 million, or $0.21 per share, compared with a net loss of $30.5 million, or $0.30 per share, in the 2025 quarter.
As of June 30, 2026, cash, cash equivalents and investments totaled $172.8 million, and management anticipates this will fund operations at least through 2027. The company highlighted advancement of AL137 as its lead ABC-enabled anti-amyloid beta antibody for Alzheimer’s disease, targeting an IND submission in Q1 2027 and first-in-human dosing in Australia no later than April 2027, alongside ongoing work on ABC-enabled siRNA programs AL064/AL164 and enzyme replacement therapy candidate AL050 for Parkinson’s disease.
Wong-Sarad Grace reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. reported that Principal Accounting Officer Grace Wong-Sarad received an award of 20,000 shares of common stock in the form of restricted stock units. These RSUs vest in 12 equal quarterly installments beginning on September 1, 2026. After this grant, she holds 115,461 shares of common stock directly, showing her equity-based compensation and alignment with the company’s performance over time.
Alector, Inc. reported that Glaxo Wellcome UK Limited (GSK) has elected to terminate their July 2021 collaboration and license agreement covering the progranulin-elevating antibodies latozinemab and nivisnebart. Under the agreement, the termination becomes effective 180 days after GSK’s July 6, 2026 notice, on January 2, 2027.
The filing links this decision to prior announcements that the Phase 3 INFRONT-3 trial of latozinemab in frontotemporal dementia and the Phase 2 PROGRESS-AD trial of nivisnebart in early Alzheimer’s disease were discontinued after not meeting key clinical goals. Alector also fully repaid and terminated its Loan and Security Agreement with Hercules Capital, returning $10,428,827.77 of outstanding principal plus accrued interest and related charges on July 8, 2026.
Yaffe Kristine reported acquisition or exercise transactions in this Form 4 filing.
Alector director Kristine Yaffe received new equity awards as part of her compensation. She was granted 28,700 restricted stock units representing shares of common stock, which vest on the earlier of June 17, 2027 or the date of Alector’s next annual meeting of stockholders.
She also received stock options for 9,450 shares of common stock, expiring on June 16, 2036. These options vest in 12 equal monthly installments beginning July 17, 2026, or fully on the earlier of the one-year anniversary of the grant date or the next annual meeting. Following the RSU grant, she directly holds 124,109 shares of common stock.
SCHELLER RICHARD H reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Richard H. Scheller reported equity compensation awards. He received 28,700 shares of Common Stock in the form of restricted stock units that vest on the earlier of June 17, 2027 or the company’s next annual stockholder meeting. Following this grant, he directly holds 134,899 shares of common stock.
He was also granted a stock option for 9,450 shares of common stock. This option vests in 12 equal monthly installments beginning July 17, 2026, or fully on the earlier of the one-year anniversary of grant or the next annual meeting, and expires on June 16, 2036.
Hammond Paula reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Paula Hammond received new equity awards in the form of restricted stock units and stock options. She was granted 28,700 RSUs that vest on the earlier of June 17, 2027 or the company’s next annual stockholder meeting. She also received a stock option covering 9,450 shares of common stock, vesting in 12 equal monthly installments beginning July 17, 2026, with full vesting no later than the earlier of one year from grant or the next annual meeting. Following these awards, Hammond directly holds 103,609 shares of Alector common stock.
Alector, Inc. reported the results of its 2026 annual meeting of stockholders. Shareholders elected three Class II directors—Elizabeth Garofalo, M.D., Errol De Souza, Ph.D., and Kristine Yaffe, M.D.—to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also ratified Ernst & Young LLP as Alector’s independent registered accounting firm for the fiscal year ending December 31, 2026, with 97,717,750 votes in favor. In addition, shareholders approved, on a non-binding advisory basis, the compensation of Alector’s named executive officers in the Say-on-Pay vote, with 58,652,335 votes for and 2,492,538 against.
GAROFALO ELIZABETH A. reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Elizabeth A. Garofalo received new equity compensation on June 17, 2026. She was granted 28,700 shares of Common Stock in the form of restricted stock units that vest on the earlier of June 17, 2027 or the date of Alector’s next annual stockholder meeting.
On the same date, she was also granted stock options covering 9,450 shares of Common Stock. These options vest in 12 equal monthly installments beginning July 17, 2026, with full vesting on the earlier of the one-year anniversary of grant or the next annual stockholder meeting, and expire on June 16, 2036. Following these awards, she directly holds 118,650 shares of Common Stock and 9,450 stock options.
Altmeyer Mark reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Mark Altmeyer reported equity awards consisting of restricted stock units and stock options. He received 28,700 RSUs representing shares of common stock, which vest on the earlier of June 17, 2027 or the company’s next annual stockholder meeting. He was also granted options for 9,450 shares of common stock, vesting in 12 equal monthly installments beginning July 17, 2026, or in full on the earlier of one year from grant or the next annual meeting. Following these awards, he directly holds 98,650 shares of common stock and 9,450 stock options.